Epigenetics is an emerging field that demands selective cell-permeable chemical probes to perturb, especially in vivo, the activity of specific
enzymes involved in modulating the epigenetic codes.
Coactivator-associated arginine methyltransferase 1 (
CARM1) is a coactivator of
estrogen receptor α (ERα), the main target in human
breast cancer. We previously showed that twofold overexpression of
CARM1 in MCF7
breast cancer cells increased the expression of ERα-target genes involved in differentiation and reduced cell proliferation, thus leading to the hypothesis that activating
CARM1 by chemical activators might be therapeutically effective in
breast cancer. Selective, potent, cell-permeable
CARM1 activators will be essential to test this hypothesis. Here we report the development of a cell-based, time-resolved (TR) FRET assay that uses
poly(A) binding protein 1 (PABP1) methylation to monitor cellular activity of
CARM1. The LanthaScreen TR-FRET assay uses MCF7 cells expressing GFP-PABP1 fusion
protein through BacMam gene delivery system, methyl-PABP1 specific antibody, and
terbium-labeled secondary antibody. This assay has been validated as reflecting the expression and/or activity of
CARM1 and optimized for high throughput screening to identify
CARM1 allosteric activators. This TR-FRET platform serves as a generic tool for functional screening of cell-permeable, chemical modulators of
CARM1 for elucidation of its in vivo functions.